DURECT Corporation (NASDAQ:DRRX) Reports robust results from DUR-928 Multi-Dose Phase 1 Study Print E-mail
By Marilyn Mullen   
Monday, 18 May 2015 20:28
DURECT Corporation (NASDAQ:DRRX) has confirmed receiving positive results from multi-dose Phase 1 clinical trial with oral formulation of DUR-928. 
Read more...
 
Q&A with PharmaCyte CEO, Kenneth L. Waggoner on PMCB’s New Direction Print E-mail
By M.E. Garza, Editor BioMedReports.com   
Monday, 18 May 2015 18:11
PharmaCyte Biotech’s recently appointed CEO, Kenneth L. Waggoner, is solely focused on hitting major milestones and marks 2015 as a banner year for PharmaCyte Biotech, Inc. (OTCQB:PMCB), a Silver Spring, MD-based clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Read more...
 
AcelRx Gets Contract from Department of Defense for ARX-04, Shares Jump Print E-mail
By William Kent   
Thursday, 14 May 2015 17:43
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX)’s shares jumped as much as 155 after the company has confirmed entering into Contract No. W81XWH-15-C-0046 amounting to $17.0 million that would be given by United States Army Medical Research and Materiel Command within the U.S. Department of Defence.
Read more...
 
NewLink Genetics Corp (NASDAQ:NLNK) Slump 28% On disappointing trial news for its algenpantucel-L Print E-mail
By Marilyn Mullen   
Tuesday, 12 May 2015 13:47
Shares of NewLink Genetics Corp. (NASDAQ:NLNK) slumped 28% to $37.53 after the company confirmed continuation of Phase 3 Immunotherapy for Pancreatic RESectable cancer Study named "IMPRESS".
Read more...
 
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) starts Phase 3 Pivotal Study of Epidiolex Print E-mail
By Josh Gee   
Monday, 11 May 2015 15:07
Biopharmaceutical firm GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has confirmed starting of Phase 3 clinical trial of Epidiolex for treating Lennox-Gastaut syndrome, a rare and severe form of childhood-onset epilepsy.
Read more...
 
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) starts Phase 3 Pivotal Study of Epidiolex Print E-mail
By Josh Gee   
Monday, 11 May 2015 15:07
Biopharmaceutical firm GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) has confirmed starting of Phase 3 clinical trial of Epidiolex for treating Lennox-Gastaut syndrome, a rare and severe form of childhood-onset epilepsy.
Read more...
 
PlasmaTech Biopharmaceutical’s New CEO Tim Miller on building a world class cell and gene therapy company focused on rare diseases Print E-mail
By M.E. Garza, Editor BioMedReports.com   
Friday, 08 May 2015 00:00
icon_qaexclusiveThis week, marked several major milestones for PlasmaTech Biopharmaceuticals, Inc. (PTBI), a Dallas and NYC-based biopharmaceutical company advancing protein biologic therapies and oncology supportive care products. Earlier in the week, business magnate, George Soros acquired a 5% stake in the biotech company.
Read more...
 
OvaScience Inc (NASDAQ:OVAS) Gains Momentum on news of AUGMENT birth Print E-mail
By Josh Gee   
Thursday, 07 May 2015 15:30
Global fertility company OvaScience Inc (NASDAQ:OVAS) has confirmed one of the first patients who got AUGMENT treatment have given birth to healthy baby boy in Toronto, Ontario, Canada.
Read more...
 
Fate Therapeutics Inc. Jumps 46% On license agreement with Juno Therapeutics Print E-mail
By Josh Gee   
Wednesday, 06 May 2015 19:07
Juno Therapeutics and Fate Therapeutics Inc. (NASDAQ:FATE) have confirmed execution of a strategic research collaboration as well as license agreement for identifying and utilising small molecules for modulation of Juno's genetically-engineered T cell product candidates in order to improve therapeutic potential for cancer patients.
Read more...
 
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) confirms initiation of Phase 1 Study of Ad-RTS-IL-12 Gene Therapy Print E-mail
By William Kent   
Tuesday, 05 May 2015 18:12
Biopharmaceutical firm, ZIOPHARM Oncology Inc.(NASDAQ:ZIOP), has confirmed initiation of Phase 1 study of Ad-RTS-hIL-12 + veledimex in patients having progressive glioblastoma or Grade III malignant glioma, a form of brain cancer.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 12

Newsletter